Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Regression of persistent corneal neovascularisation after topical anti-VEGF treatment

Poster Details

First Author: M.Banteka GREECE

Co Author(s):    L. Mavroudis   A. Nikolakopoulos                 

Abstract Details


Explore the feasibility of topical anti-VEGF treatment in persistent corneal neovascularisation(CN) and opacities due to severe alkali burns, recurrent pterygiums and corneal infections. There is no financial interest regarding this paper.


Thessaloniki Orasi - Ophthalmic Microsurgery Day Clinic


3 representative cases treated with subconjunctival injection of Bevacizumab followed up with repeated Anterior Chamber digital imaging. Case 1: chemical burn patient with CN and marked lipid deposition. Case 2: recurrent pterygium operated also with amniotic membrane graft and signs of CN over the graft. Case 3: CN and lipid deposition after severe herpetic corneal infection. Several treatment options were followed before the subconjunctival injection of Bevacizumab.


CN regressed after the injection of Bevacizumab in all cases. Treatment was repeated per needed in each case. The centre of vision has cleared of new vessels and lipid deposition.


Topical steroids and NSAIDs are a primary mode of treatment for CN. Argon laser coagulation, diathermy and cautery of large feeder vessels have also been used. Studies target the use of different anti-VEGF agents, delivery techniques and combination of these schemes. Results seem to be more effective on recent onset new vessels as they have not been sheathed with pericyte cells, which could cause resistance to anti-VEGF drugs. We found the use of bevacizumab injected subconjuctivally, highly effective for the treatment of CN. Follow up of the patient is crucial since recurrence commonly appears and retreatment is needed.

Financial Disclosure:


Back to Poster listing